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Oral squamous cell carcinoma
Background: Galectin-3 is a lectin that presents pivotal roles in tumor biology and there are no studies
evaluating their expression in dysplasias and carcinomas developed from tongue carcinogenesis models.
Aims: To investigate the role of galectin-3 in the development of tongue carcinomas using a mouse model of
oral carcinogenesis.
Methods: Galectin-3-deﬁcient (gal3−/−) and wild-type (gal3+/+) mice were challenged with 4-nitroquinoline-
1-oxide in drinking water for 16 weeks and killed at different times. Tongues were removed and the number of
dysplasias and carcinomaswas counted. An immunohistochemical study for galectin-3wasperformedonly in the
tongue from gal3+/+ mice.
Results: In both groups, a reduction of dysplasias and an increase of carcinomas from week 16 to week 32
(pN0.05) were observed. A predominance of high cytoplasmic and nuclear galectin-3 expression was observed
in carcinomas (64.7%) and dysplasias (55.5%), respectively (pN0.05). The perilesional areas always presented a
statistical cytoplasmic and nuclear galectin-3 overexpression.
Conclusions: Absence of galectin-3 did not directly affect the process of carcinogenesis and a cytoplasm shift of
galectin-3 seems to be associated with development of tongue carcinomas.
© 2010 Elsevier Inc. Open access under the Elsevier OA license.Introduction
Galectin-3 is a β-galactoside binding protein that has extensively
attracted attention due to the range of its activities, although
sometimes contradictory, in different tissues and cells (Liu and
Rabinovich, 2005). Recent works showing that galectin-3 participates
in different steps related to cancer have also demonstrated that it is a
tissue–cell depending on what compartment is present inside the
cells. In addition, other studies have demonstrated that this lectin
participates in the development and progression of tumors (Cvejic
et al., 2005; Vereecken et al., 2005; Weinberger et al., 2007). With
respect to galectin-3 immunoproﬁle in tumors, an inconsistency of
results has been observed in the literature (Piantelli et al., 2002;
Puglisi et al., 2004; Weinberger et al., 2007). As an example, tumors of
thyroid and stomach have shown to present an up-regulation oflândia-Campus Umuarama, Av.
ia-Patológica, CEP: 38405-900,
la).
vier OA license.galectin-3 expression, whereas tumors of skin, ovary, and breast have
exhibited a down-regulation (Dumic et al., 2006). Conﬂicting results
have also been observed in head and neck carcinomas, with some
studies showing tumors presenting high and others low expression of
galectin-3 (Honjo et al., 2000; Plzák et al., 2004). In tongue
carcinomas, an increased cytoplasmic galectin-3 expression was
associated with tumor progression. In addition, a reduced cytoplasmic
galectin-3 expression was signiﬁcantly associated with favorable
survival rate (Honjo et al., 2000). On the other hand, an absence of
correlation between survival and nuclear/cytoplasmic galectin-3
expression was found in esophageal carcinomas (Shibata et al., 2005).
Mouse models of tumor induction are excellent approaches to
clarify the molecular mechanisms involved in tumor development
(Vairaktaris et al., 2008). Based on this, two recent studies have
evaluated the inﬂuence of galectin-3 in the development of intestinal
and pulmonary tumors inmice (Abdel-Aziz et al., 2008; Eude-Le Parco
et al., 2009). However, the results achieved from both were clearly
discrepant. While in the study of Abdel-Aziz et al. (2008) a lower
incidence of lung tumors was observed in galectin-3-deﬁcient mice
after treatment with a potent carcinogen, Eude-Le Parco et al. (2009),
190 P.R. de Faria et al. / Experimental and Molecular Pathology 90 (2011) 189–193in contrast, showed that the absence of galectin-3 did not affect tumor
progression and the development of metastasis in mice. With respect
to the role of galectin-3 in the promotion of fully malignant
transformation of tongue epithelium, the investigation of this through
the induced-tumor carcinogenesis models has not been carried out, as
also the pattern of galectin-3 expression from dysplastic changes to
invasive carcinomas developed during oral carcinogenesis.
So, to know in what extension galectin-3 is involved in the
development of oral carcinomas, we have exploited awell-established
4-nitroquinoline-1-oxide-induced tongue carcinogenesis model in
galectin-3-deﬁcient (gal3−/−) and wild-type (gal3+/+) mice. The
main goal of this study was to evaluate comparatively the number of
gal3−/− and gal3+/+mice affected by dysplasia and carcinoma as well
as the frequency of these lesions in both groups. In addition, as the
signiﬁcance of galectin-3 expression by immunohistochemistry
remains unsolved and at the same time contradictory for numerous
malignancies, we also address in this report the pattern of galectin-3
expression during the carcinogenesis process to understand how its
expression in terms of intensity and location may differ among
dysplasias, carcinomas, and their respective perilesional areas from
gal3+/+ mice.
Materials and methods
The experiment was approved by the Committee on Animal
Experimentation of the Universidade Federal de Uberlândia (protocol
number 038/09).
Animals
Gal3−/− mice generated through homologous recombination and
backcrossed to C57BL/6 mice were generously provided by Hsu's
group (Hsu et al., 2000). Forty-two six-week-old male gal3−/− mice,
weighing from 21 to 23 g, were used. Sex- and age-matched gal3+/+
mice with the same genetic backgroundwere used as control. All mice
were maintained under controlled conditions of temperature (22 °C),
light–dark periods of 12 h and free access to commercial diet.
Experimental protocol
To study the carcinogenesis process, gal3+/+ and gal3−/− mice
were randomly separated and killed at three time points after the end
of treatment with carcinogen 4NQO, as follows: at week 16, week 24,
and week 32. For tumor induction we used the protocol described by
Tang et al. (2004) with some modiﬁcations. The carcinogen 4-
nitroquinoline-1-oxide (SIGMA CO, MO, USA) was diluted only in
water to achieve a concentration of 100 μg/ml and administered orally
for 16 weeks. It was prepared weekly and the bottles were reﬁlled
once a week. At the end of week 16, the treatment was stopped and
both groups of mice drank only tap water until euthanasia, with
exception of two groups of gal3+/+ and gal3−/− mice that were
scheduled to be killed after the terminus of treatment.
Histopathological analysis
All gal3+/+ and gal3−/− mice were killed by cervical dislocation
under deep ether anesthesia. The tongues of all mice were removed
and cut transversally in ﬁve fragments. Great care was taken when a
visible lesion was found on the tongue surface. In this case, the lesion
was carefully cut to permit its complete study on microscopic as well
as other fragments of the same tongue to exclude other microscopical
changes. All tissues were ﬁxed in a 10% neutral-buffered formalin
solution for 24 h, embedded in parafﬁn blocks, and stained with
hematoxylin and eosin for histological examination. We used the
criteria described by Lumerman et al. (1995) and Slootweg and
Eveson (2005) to identify areas of dysplasias and carcinomas,respectively. All histological slides were blindly and independently
examined by three well-trained pathologists (PRF, AML, and SVC).
Subsequently, consensus scoring using a multihead microscope was
used to solve any discrepancies. When two or more areas of epithelial
alterations were presented in the same histological slide, the highest
grade epithelial lesion was taken as representative to determine
which pathologic alteration each mouse had. In addition, the
frequency of tumors diagnosed microscopically in the tongue for
each animal was determined.
Immunohistochemistry for galectin-3
Samples of dysplasias and carcinomas diagnosed microscopically
in gal3+/+ mice were used to determine the pattern of galectin-3
expression. For this, an immunohistochemical assay using the avidin–
biotin–peroxidase method was performed on 3 μm-thick sections
mounted on 3-aminopropyltrietoxy-sylane-coated glass slides. After
deparafﬁnization and hydration, sections were submitted to antigen
retrieval with citrate buffer (10 mM, pH 6.0 using a pressure cooker
for 4 min, at 120 °C). Endogenous peroxidase activity was blocked
with 3% H2O2 for 15 min, and the slides were preincubated with a
protein block solution (1% skim milk, 0.05% Triton X, and phosphate-
buffered saline [PBS]) for 20 min at room temperature to prevent non-
speciﬁc binding. Immunostaining was obtained by incubating the
primary monoclonal antibody against galectin-3 (TIB 166 hybridoma,
from American Type Culture Collection and kindly provided by Roger
Chammas), diluted at 1:30 in a humid chamber at 4 °C overnight. The
reaction was developed with chromogen 3,3′-diamino-benzidinete-
trahydrochloride (Sigma-Aldrich, USA) and the sections were coun-
terstained with Harris' hematoxylin. As a negative control, the PBS
solution was substituted for the primary antibody. Fragments of
papillary carcinoma from the thyroid gland with known positivity for
galectin-3 were used as control.
Cytoplasmic and nuclear galectin-3 expression was assessed
separately in dysplasias, carcinomas, and their respective perilesional
areas. We considered the perilesional area as being the region of the
epithelium tissue placed adjacent to both lesions. As in these areas
some histological alterations could be seen, we took care to analyze
only the region of the epithelium which presented changes on
microscopic view different to the main lesion. Brieﬂy, the intensity of
staining was scored, as follows: 0, from negative to minimal staining
(b10% of cells); 1+, for those tumors showing a weak staining and
over 10% of cells; 2+, for those tumors presenting amoderate staining
and over 10% of cells; and 3+, for those tumors presenting a strong
staining and over 50% of cells (Weinberger et al., 2007).
Statistical analysis
The incidence of dysplasias and carcinomas between gal3+/+ and
gal3−/− mice was determined by chi-square test. We also evaluated
the expression of galectin-3 among carcinomas, dysplasias, and their
respective perilesional areas from gal3+/+ mice. For this, we
categorized its expression into two groups: low (0 and 1+) and
high expressors (2+ and 3+). So, to determine a possible association
between dysplasia×perilesional area, carcinoma×perilesional area,
and carcinoma×dysplasia in relation to galectin-3 expression, we
made a contingency table for each crossing and analyzed with Fisher
exact test. P-values less than 0.05 were considered signiﬁcant to reject
the null hypothesis.
Results
Fig. 1 depicts the evolution of tongue carcinogenesis in gal3+/+
and gal3−/−mice. In both groupswe could observe a steady reduction
of mice with dysplastic changes in the tongue epithelium from week
16 to week 32, while the number of mice that had carcinoma showed
Fig. 1. Frequencies of dysplasias and carcinomas found in gal3−/− and gal3+/+ mice according to the different time points of the experiment (wk: week).
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week 32, both the histopathological changes were found in different
regions of the same tongue showing that the carcinogenesis process
was multifocal. Although dysplastic changes were found in mild,
moderate or severe forms, all carcinomas were histopathologically
graded as well-differentiated. In addition, in all the experimental
periods, the number of mice affected by carcinoma was always higher
in gal3+/+ than in gal3−/− mice, especially at week 32. With respect
to the tumor number/mice, it was found that 35.7% of gal3+/+ mice
presented three or more carcinomas on the tongue, in detriment of
only 18.1% of the gal3−/− mice. However, the statistical processing
yielded no differences, as detailed in Table 1.
Immunohistochemical ﬁndings
Overall, the proﬁles of galectin-3 expression in the normal
epithelium, epithelial dysplasias, carcinomas and their perilesional
areas were remarkably distinct. The staining in cells from the basal
layer of the normal epithelium was predominantly negative, but the
focal areas of weak immunoreactivity either in the cytoplasm or
nucleus aswell as in both compartments altogether could be observed.
On the other hand, cells placed in the upper layers almost always
depicted a stronger immunostaining in both cell compartments.
Curiously, some areas of the normal epithelium were possible to
detect galectin-3 immunoreactivity on the plasma membrane. In
dysplasias and carcinomas we could observe obvious differences as
compared with their perilesional areas, but not between them.
Galectin-3 expression was always lower in dysplasias and carcinomas
than in their respective perilesional areas. Moreover, cells expressing
galectin-3 either cytoplasmic and/or nuclear pattern could be
observed in these lesions. As expected, strong staining nearest to the
keratinized areas of neoplastic islets was visualized. One interesting
aspect was that cells from both lesions and adjacent to the stromaTable 1
Number of gal3+/+ and gal3−/− mice presenting carcinomas distributed according to







TN b3 TN ≥3 %
16 gal3+/+ 8 4 4 0 50.0
gal3−/− 10 2 2 0 20.0
24 gal3+/+ 8 5 5 1 62.5
gal3−/− 7 4 4 1 57.1
32 gal3+/+ 5 5 1 4 100.0
gal3−/− 6 5 4 1 83.3
TN: tumor number per mouse.
N° = number.presented an absence and sometimes a weak galectin-3 expression, as
evidenced in the basal layer of the normal epithelium (Fig. 2).
A predominance of cytoplasmic galectin-3-overexpressing carci-
nomas (64.7%) was observed. On the other hand, an inverse pattern of
galectin-3 expression was noted in the dysplasias in which an
elevated number of lesions presenting nuclear galectin-3 overexpres-
sion (55.5%) were found. Although no statistical difference was
reached with these results, they seem to suggest that a shift in the
immunolabeling from the nuclear to the cytoplasm for galectin-3
overexpression during carcinogenesis process might indicate an early
change in the development of tongue carcinomas. When analyzing
comparatively galectin-3 expression among dysplastic changes,
carcinomas and their respective perilesional areas, we could ﬁnd
that the staining in the epithelium tissue adjacent to both the lesions
always presented a statistical cytoplasmic and nuclear galectin-3
overexpression, indicating that a decreased galectin-3 expression in
both compartments of the cells may be associated with malignant
transformation (Table 2).
Discussion
The major aim of the present work was to study the inﬂuence of
galectin-3 in the incidence of dysplasias and carcinomas during
experimental oral carcinogenesis. For this, we used a well-established
mouse model of tongue carcinogenesis induced by the carcinogen
4-nitroquinoline-1-oxide in two types of animals: gal3+/+ and
gal3−/− mice. Here, we observed during all periods of time, i.e. at
weeks 16, 24 and 32, that the number of gal3+/+ and gal3−/− mice
affected by carcinomas showed a steady increment, especially in the
gal3+/+ mice, but no statistical difference was found, showing that
the absence of galectin-3 does not directly present a role in the
development of tongue carcinomas after chemical treatment. It was
differently found by Abdel-Aziz et al. (2008), who using a model of
lung carcinogenesis induced by a potent tobacco carcinogen found
that the proportion of lung tumors was statistically different between
gal3+/+ and gal3−/−mice. On the other hand, our results were similar
to the data obtained by Eude-Le Parco et al. (2009), who did not ﬁnd
any inﬂuence of the absence of galectin-3 in the development of
intestinal and mammary tumors, including the dissemination of
tumors into the lung.
Alteration in galectin-3 expression has been observed in different
malignancies, but the results published until now have been
contradictory. In breast, vulvar, cervical and colon carcinomas, a
decreased galectin-3 expression has been frequently observed during
tumor progression, but not for vulvar, bladder, and gastric carcinomas
(Bresalier, 1997; Betka et al., 2003; Castronovo et al., 1996; Lee et al.,
2006; van den Brûle et al., 2004). Although there are not any
explanation for these contradictory results, intra- and inter-tumoral
Fig. 2. Immunostaining of galectin-3 in the epithelial tongue throughout the different stages of experimental carcinogenesis. (A): Normal epithelium showing strong immunostaining
in the cytoplasm and nucleus of keratinocytes from the intermediate to the superﬁcial layers. Note a weak and/or an absence of galectin-3 expression in the basal layer. (B) and
(C): Epithelial dysplasias showing reduced expression of galectin-3. Note the distinct pattern of galectin-3 expression in the perilesional areas. (D): Expression of galectin-3 in a
carcinoma. (E): The same lesion showing the differential pattern of galectin-3 expression between cells nearest a keratin pearl and those cells adjacent to connective tissue.
192 P.R. de Faria et al. / Experimental and Molecular Pathology 90 (2011) 189–193heterogeneity, tissue-speciﬁc functions of galectin-3, and complex
patterns of expression among galectins in different tumors have been
considered (Lahm et al., 2001; Lee et al., 2006). Here, we showed that
the intensity of galectin-3 expression was always statistically higher
in both cytoplasm and nucleus of the normal epithelium placed
adjacent to dysplastic changes and carcinomas. In contrast, anTable 2
Distribution of the sample according to the intensity and location of galectin-3





Low (n/%) High (n/%) Low (n/%) High (n/%)
Dysplasia 36 19/52.7a 17/47.3c 16/44.4e 20/55.6g
Perilesional area 36 6/16.7b 30/83.3d 3/8.3f 33/91.7h
Carcinoma 17 6/35.3i 11/64.7k 10/58.8m 7/41.2o
Perilesional area 17 0/0j 17/100l 0/0n 17/100p
Fisher exact test: [a vs. b vs. c vs. d] p=0.002; [e vs. f vs. g vs. h] p=0.001; [i vs. j vs. k vs.
l] p=0.01; [m vs. n vs. o vs. p] p=0.0003; [a vs. c vs. l vs. k] p=0.25; and [e vs. g vs.m vs.
o] p=0.38.increased expression of this lectin has been detected in both
hypopharyngeal and laryngeal carcinomas in comparison with
normal epithelium and dysplasia (Saussez et al., 2008). The ﬁndings
of the current study give support to the accumulated evidence linking
decreased levels of galectin-3 expression and regressive alterations in
the normal epithelium that might culminate to tumorigenesis
(Gillenwater et al., 1996; Lee et al., 2006; Takenaka et al., 2003).
We observed a predominance of high nuclear galectin-3 expression
in the dysplasias and, on the other hand, overexpression of cytoplasmic
galectin-3 in carcinomas. Although no statistical difference was found
with these results probably due to a small number of carcinomas found,
this study suggests that during the progression from dysplasia to
cancerous status a shift from nuclear to cytoplasm galectin-3 over-
expression seems to occur. The presence of galectin-3 in the nucleus or
cytoplasm seems to be associated with tumor progression in certain
neoplasms, but not all (Honjo et al., 2000; Mathieu et al., 2005; Shibata
et al., 2005). In tongue carcinomas, cytoplasmic galectin-3 expression
increased during tumor progression (Honjo et al., 2000). Similarly, in
vulvar squamous lesions, an up-regulation of cytoplasmic galectin-3
expression has also been shown (Brustmann, 2006). In contrast, in
esophageal carcinomas galectin-3 staining was detected in both the
193P.R. de Faria et al. / Experimental and Molecular Pathology 90 (2011) 189–193nucleus and cytoplasm, with the highest level observed in the latter
(Shibata et al., 2005). It is possible to speculate that this pattern of
galectin-3 expressionwhich changed between dysplasia and carcinoma
may be associated with malignant transformation of the tongue
epithelium.
Taken as a whole, our results suggest that the absence of galectin-3
did not affect directly the process of carcinogenesis and a shift in the
immunolabeling from the nucleus to the cytoplasm of galectin-3
overexpression may be associated with development from a precan-
cerous state to a cancerous condition.
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